The membrane-anchored matrix metalloproteinase-regulator RECK is often downregulated in cancers; in some cases, a significant correlation between the level of residual RECK in resected tumors and patient survival has been noted. Furthermore, restoration of RECK expression in certain cancer-derived cell lines results in reduced tumorigenicity. Here we report that acute RECK expression in colon carcinoma cells results in cell cyclearrest accompanied by downregulation of a ubiquitin ligase component, S-phase kinase-associated protein 2 (SKP2), and upregulation of its substrate, p27 KIP1 . Our data indicate that RECK-induced growth suppression is at least partially dependent on p27, and that RECK and type I collagen share similar effects on the SKP2-p27 pathway. Importantly, in patients with lung, colorectal and bladder cancers, the RECK/SKP2 ratio is high in normal tissues and lower in the cancer tissues. These findings reveal a novel molecular pathway linking cellcycle progression to RECK downregulation, extracellular matrix degradation and SKP2 upregulation, and suggest that treatment regimens that induce RECK expression could be promising cancer therapies.
Introduction
Protein phosphorylation (through the activity of cyclindependent kinases (CDKs)) and protein degradation (through the ubiquitin-proteasome pathway) have major roles in cell-cycle regulation. Recent evidence indicates the importance of S-phase kinase-associated protein 2 (SKP2) upregulation and consequent p27 KIP1 downregulation in various cancers (Zhu, 2010) . SKP2 is a component of a SKP1-CUL1-F-box-protein (SCF)-type ubiquitin ligase complex (termed SCF SKP2 ); known substrates of this complex include three CDK inhibitors: p21 (CDKN1A, Cip1 and WAF1), p27 (also known as CDKN1B and KIP1) and p57 (CDKN1C, KIP2 and BWS) (Frescas and Pagano, 2008) . SKP2 upregulation therefore accelerates p27 degradation, leading to deregulated CDK activity and cell-cycle progression as found in cancer cells.
RECK was first isolated as a transformation-suppressor gene by cDNA expression cloning (Noda et al., 1989; Takahashi et al., 1998) and found to encode a membraneanchored regulator of several extracellular metalloproteinases, including MMP2, MMP7, MMP9, MT1-MMP, ADAM10 and CD13 (Takahashi et al., 1998; Oh et al., 2001; Miki et al., 2007; Muraguchi et al., 2007; Omura et al., 2009 ). These proteases have been implicated in tissue remodeling and cleavage of various extracellular molecules under normal and pathological conditions (Sternlicht and Werb, 2001 ). RECK mRNA is detectable widely in normal human organs but is undetectable in a number of cell lines derived from human tumors (Takahashi et al., 1998; Loayza-Puch et al., 2010) . Downregulation of RECK is found in a wide variety of tumors, and, in some cases, a significant correlation between the level of residual RECK in resected tumors and patient survival has been noted . In xenograft models, restored RECK expression in cancer cells results in reduction in tumor angiogenesis, invasion, metastasis (Takahashi et al., 1998; Oh et al., 2001) and, depending on the cell line employed, reduced tumorigenicity (LoayzaPuch et al., 2010) . Thus, RECK downregulation is likely to be an important step towards, rather than a result of, carcinogenesis.
Reck-deficient mice die around embryonic day 10.5 with reduced tissue integrity (accompanied by dramatic reduction in collagen fibrils), arrested vascular development and precocious neuronal differentiation (Oh et al., 2001; Muraguchi et al., 2007; Chandana et al., 2010) . Embryo fibroblasts derived from these mice show unstable focal adhesions, increased speed of migration and reduced directional persistence during migration, and the phenotype can be partially suppressed on fibronectin-coated dishes . These studies, taken together with the effects RECK has on tumorigenesis, indicate that RECK functions via its effects on cell-cell and cell-extracellular matrix interactions. The effect of RECK on intracellular signaling pathways, however, remains largely unexplored. In particular, previous studies used stable manipulations of RECK gene activity (for example, stable transfections and global gene knockouts) to explore the functions of RECK (Noda et al., 2003; Noda and Takahashi, 2007) , but if RECK has negative effects on essential signaling pathways, such as those that affect cell proliferation or viability, stable manipulation of RECK would result in the selection of populations with resistance to, or functional compensations for, RECK activity. Therefore, we took advantage of the high efficiency and synchrony of adenovirus-mediated gene transfer to allow us to study the effects of acute RECK expression in cancer cells. Our data indicate that RECK can suppress cell proliferation and induce cellular senescence when acutely expressed in cancer cells, and that at least a part of these effects can be attributed to downregulation of SKP2 and consequent upregulation of p27. These findings have revealed an important link between the inhibition of extracellular proteolysis by RECK and the inhibition of intracellular proteolysis by the ubiquitinproteasome system. They also suggest that RECK reactivation may be a promising new strategy for manipulating the SKP2-p27 pathway in cancer cells.
Results

Biological effects of acute RECK expression in malignant cells
To study the effects of acute RECK expression in cancer cells, we generated an adenoviral vector containing a human RECK cDNA (Ad-RECK). When this virus was infected into a v-K-ras-transformed NIH3T3 subline, DT (Noda et al., 1983) , the cells, as expected, showed increased RECK expression ( Figure 1a ) and increased spreading ( Figure 1b) . We determined the gene expression profiles of DT cells infected with the control virus (Ad-Z) or Ad-RECK using Affymetrix Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara, CA, USA). Through pathway analysis using the FunNet algorithm (Prifti et al., 2008) , we detected significant upregulation of two pathways and downregulation of nine pathways after RECK expression (Table 1a) . These changes largely implicate RECK in regulation of cellular metabolism and proliferation.
We also examined the effects of Ad-RECK in SW620, a cell line derived form a metastatic lesion of colon adenocarcinoma (Leibovitz et al., 1976) . At 48 h after infection, the cells infected by Ad-RECK were significantly fewer in number (Figure 1c , panels 5 and 6) as compared with the controls (Figure 1c , panels 1-4). Cell-cycle analysis indicated that after RECK expression, the cells in the G1 phase of the cycle increased, whereas the cells in the S phase decreased, and the sub-G1 populations stayed low (Figure 1d , panels 3 and 4), indicating the occurrence of cell-cycle arrest rather than apoptosis. Moreover, the Ad-RECK-infected cells showed elevated b-galactosidase activity at pH 6 (Figure 1e , panel 3), suggesting the induction of cellular senescence (Dimri et al., 1995) .
RECK induces SKP2 downregulation and p27 upregulation in SW620 cells
To address the question of how RECK induces cellular senescence in SW620 cells, we determined the gene expression profiles of the cells infected with Ad-Z or Ad-RECK using Affymetrix Human Genome U133Plus 2.0. Arrays (Affymetrix). Using the FunNet algorithm, however, we were unable to determine which pathways affected by RECK led to cell-cycle arrest (Table 1b) . In an attempt to find individual genes that were both altered by RECK and relevant to the observed bioactivity, we filtered the data using gene ontology terms such as cell proliferation (GO:0008283), cell cycle (GO:0007049) and G1/S transition of the mitotic cell cycle (GO:0000082). Through this approach, we found a modest (B0.5-fold) downregulation of SKP2 (Figure 2a) , which raised the interesting possibility that the major substrates of SKP2 (for example, the CDKinhibitors p21, p27 and p57) may serve as effectors of RECK to induce cell-cycle arrest.
Our microarray data indicated that p27 mRNA is detectable but not much affected by RECK expression in SW620 cells, and that the levels of p21 and p57 mRNAs are low in these cells (Figure 2a ). SKP2 downregulation after RECK expression and the little effects of RECK on p27 expression were also confirmed by RT-PCR ( Figure 2b, lanes 1-3) . At the protein level, however, SKP2 downregulation was accompanied by a significant upregulation of p27 (Figure 2c, lane 3) , which is consistent with the widely accepted model that SKP2 promotes p27 degradation.
We also examined the levels of SKP2 and p27 in another human tumor cell line, H1080 fibrosarcoma (Rasheed et al., 1974) , stably transfected with a control plasmid vector (V) or the vector expressing RECK (R) (Figure 2d ). The cells expressing RECK grew more slowly than the control cells (Figure 2e ), and SKP2 downregulation (both at the mRNA and protein levels) and p27 upregulation (at the protein level) were also observed ( Figure 2b , lane 5; Figure 2d , lane 2). Small interfering RNA (siRNA)-mediated knockdown of RECK also resulted in SKP2 upregulation and p27 downregulation ( Figure 2f , lane 4), indicating an active role for RECK in regulating the levels of SKP2 and p27 in this system. Hence, in two tumor-derived cell lines (SW620 and HT1080), RECK expression was found to induce SKP2 downregulation and p27 upregulation. Does a similar link between RECK and the SKP2-p27 pathway exist in nonmalignant cells? We addressed this question using two systems. First, in the mouse fibroblast cell line NIH3T3, the level of endogenous Reck is known to heavily depend on cell density (Hatta et al., 2009 ). Here we found that the level of Reck at different cell densities was inversely correlated with the level of SKP2 and positively correlated with the level of p27 (Figures 2g and h) . Second, in a mouse embryo fibroblast (MEF) line derived from a tamoxifeninducible conditional Reck-knockout mouse, inactivation of endogenous Reck gene by treatment with 4-hydroxytamoxifen (OHT) resulted in SKP2 upregulation and p27 downregulation ( Figure 2i ). These findings not only demonstrate the correlation among the levels of Reck, SKP2 and p27 in nonmalignant cells but also indicate the active role for Reck in the regulation of SKP2 and p27 expression.
The role of p27 in RECK-mediated growth suppression in SW620 cells To assess the role of p27 in RECK-mediated growth arrest, we treated SW620 cells for 24 h with the control siRNA (si-C) or an siRNA-targeting p27 (si-p27) and then infected with either Ad-Z or Ad-RECK and incubated for additional 72 h (Figure 3 ). Under these conditions, Ad-RECK alone had an effect to suppress the cell number (probably via cell-cycle arrest, Figure 1d ) to about 40% These results suggest that p27 has an active role in RECKinduced growth suppression and senescence. Possible mechanisms by which RECK downregulates SKP2 How does RECK downregulate SKP2? RECK, a membrane-anchored glycoprotein, is unlikely to regulate gene expression directly; RECK is more likely to regulate proteolysis of some molecules in the vicinity of the cell surface, thereby affecting intracellular signaling and gene expression. Several lines of evidence implicate RECK in the protection of extracellular matrix components through inhibition of extracellular proteases (see Introduction). We therefore tested the effects of two major extracellular matrix components, type I collagen and fibronectin on SKP2 expression in SW620 cells (Figures 4a and b) . Interestingly, SKP2 expression was strongly suppressed when the cells were plated on type I collagen ( Figure 4a , lane 2) but not on fibronectin ( Figure 4b , lane 2). In fact, collagenolytic activity of SW620 cells was greatly diminished after Ad-RECK infection, as visualized by in situ zymography using DQ type I collagen (Figure 4c ). We also found that the effect of type I collagen to downregulate SKP2 could be suppressed by the protein kinase C inhibitor GF109203X (Toullec et al., 1991) (Figure 4e ) and the Rho-family GTPase inhibitor toxin B (Just et al., 1995) (Figure 4f ), but not by the Src inhibitor PP2 (Hanke et al., 1996) (Figure 4d ). Protein kinase C and Rhofamily GTPases are known to be involved in integrin signaling (Caswell et al., 2009) . Importantly, the SKP2 downregulation induced by RECK was also sensitive to GF109203X and toxin B (Figures 4g and h ), suggesting that type I collagen and RECK share a common signaling pathway (for example, integrin signaling) in downregulating SKP2.
The levels of RECK and SKP2 in human tissues SKP2 upregulation (Zhu, 2010) and RECK downregulation (Figure 5a ). Second, among 60 urinary bladder tissues (Dyrskjot et al., 2004) , high-RECK/low-SKP2 profiles were found mainly in normal urothelium, normal mucosa and carcinoma in situ, whereas low-RECK/high-SKP2 profiles were found in more malignant tumors: superficial transitional cell carcinoma and muscle invasive carcinoma (Figure 5b ). Third, among 108 lung tissues (Landi et al., 2008) (Figure 5c ), high-RECK/low-SKP2 profiles were found in normal tissues (right half) and low-RECK/high-SKP2 profiles were found in tumor tissues (left half) with only a few exceptions. These data demonstrate that a direct inverse correlation between the levels of RECK and SKP2 is found in lung, colon and bladder tissues and that a low-RECK/high-SKP2 ratio shows strong association with malignancy in these tissues.
Discussion
In this study, we demonstrated that RECK expression suppresses cell proliferation of three malignant cell lines: DT, SW620 and HT1080. RECK is downregulated by multiple signaling pathways at multiple levels ( Our data are consistent with the model that RECK inhibits cell division by protecting pericellular extracellular matrix (for example, collagens), thereby enhancing integrin signaling that leads to SKP2 downregulation and consequent p27 upregulation (Figure 6 ). The previous findings that Rac1 downregulates SKP2 in rat vascular smooth muscle cells (Bond et al., 2008) and that b1 integrin downregulates SKP2 and suppresses proliferation of the hepatocellular carcinoma line SMMC-7721 (Fu et al., 2007) are in agreement with this model. Not surprisingly, not all cancer cells respond in the same manner to b1 integrin. In the hepatocellular carcinoma line HepG2, for example, b1 integrin signaling enhances SKP2 expression (Zhang et al., 2003) . Hence, detailed molecular mechanisms underlying how cancer cells can evade RECK-induced SKP2 downregulation need to be clarified in future studies.
Skp2-deficient mice are reported to be smaller than normal, and their embryo fibroblasts (MEFs) grow more slowly than wild-type MEFs (Nakayama et al., 2000) . These phenotypes are alleviated in Skp2/p27 double mutant mice (Nakayama et al., 2004) , suggesting that p27 overexpression is the cause of these phenotypes (Lin et al., 2010) . This is consistent with our finding that RECK (which downregulates SKP2) induces cellular senescence in SW620, a cell line carrying mutations in KRAS and p53. p27-deficient mice, on the other hand, are reported to show gigantism and pituitary tumors (Frescas and Pagano, 2008) . If p27 is a major effector of RECK, Reck-deficient mice and p27-deficient mice would be expected to show some overlapping phenotypes. Global Reck-deficient mice, however, die too early (Oh et al., 2001; Muraguchi et al., 2007) and provide no direct answers to this question; the embryonic lethality of Reck-deficient mice probably reflects the multiplicity of RECK targets/effectors that are essential for embryogenesis. Phenotypes of hypomorphic and/or conditional Reck-knockout mice may provide more useful information in this regard.
It is presently unclear why the siRNA-mediated knockdown of p27 could rescue the proliferation of Ad-RECK-infected cells only partially (Figure 3c , bar 9). One possibility is that RECK suppresses cell proliferation through multiple mechanisms, and this could be at the levels of SKP2 targets as well as RECK targets.
The transcriptome data in the public database (Dyrskjot et al., 2004; Sabates-Bellver et al., 2007; Landi et al., 2008) (Figure 5 ) strongly support the clinical relevance of our findings. As SKP2 is a promising target of cancer therapy (Frescas and Pagano, 2008; Zhu, 2010) , the newly discovered link between RECK and SKP2 may open a new avenue to the therapeutic manipulations of this important pathway. We recently reported on an assay system for screening chemicals that activate Reck transcription (Murai et al., 2010) . One possible approach would be to use such chemicals to induce RECK expression and consequent SKP2 downregulation in cancer cells. (panels 1-3) , the control siRNA (panels 4-6) or the p27 siRNA (panels 7-9) were left uninfected (mock; panels 1, 4 and 7) or infected with either Ad-Z (panels 2, 5 and 8) or Ad-RECK (panels 3, 6 and 9) and incubated for 72 h. Scale bar: 100 mm. (c) Effects of p27 siRNA on Ad-RECK-induced reduction in cell number. Cells treated as described in b were counted. The data are presented as the ratios to the vehicle-treated controls. Bar represents mean ± s.e.m. (n ¼ 3). (d) Effects of p27 siRNA on Ad-RECK-induced activation of senescence-associated b-galactosidase. Cells treated as described in a were subjected to X-gal staining at pH 6. Scale bar: 50 mm.
Materials and methods
Cell lines and recombinant adenoviruses NIH3T3, DT, SW620, HT1080 and HT1080 transfectants were maintained in growth medium as described previously (Oh et al., 2001; Hatta et al., 2009) . The 3.2-kb Mlu1-Msc1 fragment of human RECK cDNA was inserted between the corresponding sites of pCAmm, a modified version of the pCAcc plasmid, to obtain pCAhRECK. The 5.2-kb Cla1 fragment (RECK expression cassette) from pCAhRECK was inserted into the ClaI site of the pAx3 cosmid vector to obtain pAx3hRECK. Replication-defective Ad-RECK virus was generated by transfecting pAx3hRECK into HEK-293 cells following the protocols described previously (Miyake et al., 1996) . The control virus expressing the bacterial lacZ gene has been described elsewhere (Yoshida and Hamada, 1997) . The MEF line (R1B2-6) was derived from a 13.5-day mouse embryo (genotype: Reck R1B/R1BD
;CAG-CreER) using the cold trypsin method (Freshney, 1987) , followed by extensive passaging at the splitting ratio of 1:3 in aMEM supplemented with 10% feral bovine serum on collagen-coated dishes. Generation of mice with Reck R1B allele (containing two loxP sites flanking Reck exon 1) will be described elsewhere (Yamamoto et al., submitted for publication). The CreER transgenic mouse (STOCK Tg(CAG-cre/Esr1)5Amc/J) was obtained from the Jackson Laboratory (Bar Habor, ME, USA). /60-mm dish) were harvested 48 h after plating. Total RNA was extracted from these cells using the RNeasy Kit (Qiagen, Hilden, Germany) was used to generate biotinylated cRNA, and the cRNA was hybridized to the Mouse Genome 430 2.0 Array (for DT) or Human Genome U133Plus 2.0 Array (for SW620 and HT1080) (Affymetrix) following the manufacturer's instructions (URL:http:// www.affymetrix.com/index.affx). The hybridization intensity was determined with Affymetrix GeneChip Scanner 3000 and normalized against controls. The lists of transcripts whose signals were increased (ratio of normalized values >2) or decreased (ratio of normalized values o 0.5) in the RECKexpressing counterparts (and positive at least in one of the two samples) were used to detect affected pathways using the II III  III IV  I  II IIIIV  I  II  IV  III  I II  III  I  I I  I I I  I V  II  I  I Stage :
Relative GeneChip Count Figure 5 The levels of RECK and SKP2 in human tissues. (a) Colorectal adenomas and normal mucosas from 32 patients (GEO accession no. GDS2947) (Sabates-Bellver et al., 2007) . The data for RECK (205407_at) and SKP2 (203625_x_at) were obtained from the GEO database (NCBI), and the ratios to the mean value of all samples (32 adenomas and 32 normal mucosas) were calculated. (b) Carcinoma in situ (CIS) lesions of the urinary bladder (GDS1479) (Dyrskjot et al., 2004) . The probes and methods are the same as (a). STCC-CIS, superficial transitional cell carcinoma with surrounding CIS lesion; STCC, superficial transitional cell carcinoma without surrounding CIS lesion; MI, muscle invasive carcinoma. (c) Cigarette smoking effect on lung adenocarcinoma (GDS3257) (Landi et al., 2008) . The probes and methods are the same as (a). F, female; M, male.
RECK regulates the SKP2-p27 pathway Y Yoshida et al online tool FunNet (Prifti et al., 2008) . The lists of normalized values were also filtered using GO-term numbers to focus on certain categories of genes. Gene expression data on human tumor samples were downloaded from the GEO profile database at NCBI (http://www.ncbi.nlm.nih.gov/sites/entrez? db ¼ geo&term).
RT-PCR
The cDNA was synthesized using total RNA (the same batches of samples used in the GeneChip assay), oligo(dT) primer (PerkinElmer, Waltham, MA, USA), and SuperScript II (Invitrogen, Carlsbad, CA, USA). The PCR amplification of cDNA fragments was performed with Taq PCR Core Kit (Qiagen), under conditions optimized for linearity of amplification, using the following primers (Takara Bio, Shiga, Japan): RECK (HA073007), p27 (HA039060), HPRT1 (HA031580) and SKP2 (sense: 5 0 -ACCTTTCTGGGTGTTCTGGA-3 0 , antisense: 5 0 -AAGATTCAGCTGGGTGATGG-3 0 ). The PCR products were separated by electrophoresis (2% agarose) and quantified using LAS-3000 (Fujifilm, Tokyo, Japan).
Immunoblot assay
Proteins in the cell lysates prepared, as described previously (Oh et al., 2001) , were quantified using the DC protein assay kit (Bio-Rad, Hercules, CA, USA), separated by SDS-PAGE (10% acrylamide) and subjected to indirect immunoblot assay using the following antibodies as primary antibodies (antigen (source)): RECK (5B11D12) (Takahashi et al., 1998) , p27 (BD Biosciences, Pharmingen, San Jose, CA, USA), SKP2 (Cell Signaling Technology, Danvers, MA, USA), and GAPDH (6C5, Ambion, Carlsbad, CA, USA). Specific bands were visualized using the Enhanced Chemiluminescence kit (Millipore, Billerica, MA, USA) and HRP-conjugated anti-mouse IgG-F(ab 0 )2 monoclonal antibody (Cell Signaling Technology) followed by recording with LAS-3000. For mouse proteins, the same antibodies were used except for Skp2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
siRNA transfection Validated siRNAs were obtained from Ambion (hRECK, #. 29149), Santa Cruz p27 KIP1 (sc-29430) and Dharmacon (Chicago, IL, USA; control duplex, D-001210-03). The cells (2.5 Â 10 5 /well) were seeded onto six-well plates with DMEM supplemented with 5% fetal bovine serum without antibiotics. Sixteen hours after plating, siRNA was transfected using Lipofectamine RNAiMAX (Invitrogen) at a final RNA concentration of 100 nM.
Cell cycle analysis Cells infected with recombinant adenovirus at an MOI of 600 were incubated for 48 h, washed twice with ice-cold phosphatebuffered saline (PBS) (À), fixed in 1% methanol in PBS for 20 min on ice and washed twice with PBS (À). The cells were resuspended in 5 ml ice-cold 70% ethanol, kept at À20 1C for 4 h, washed twice with PBS (À) containing 0.1% Triton X-100 and 5 mg/ml bovine serum albumin, resuspended in 1 ml PBS (À) containing 20 mg/ml propidium iodide, 250 mg DNase-free RNaseA and incubated at room temperature for 30 min in the dark. The stained cells were analyzed using FACScan (Becton Dickinson, Franklin Lakes, NJ, USA) with the CELLQuest software.
Detection of senescence-associated b-galactosidase Senescence-associated b-galactosidase activity was detected as previously described (Dimri et al., 1995; Serrano et al., 1997) with some modifications. Briefly, the cells were washed once with PBS (À) (pH 7.2), fixed with 0.5% glutaraldehyde (PBS (À) (pH 7.2)), washed in PBS (À) (pH 6.0) containing 1 mM MgCl 2 and incubated in X-gal solution (1 mg/ml X-gal (Nacalai, Kyoto, Japan), 0.12 mM K 3 Fe(CN) 6 , 0.12 mM K 4 Fe(CN) 6 and 1 mM MgCl 2 in PBS at pH 6.0) for 10 h at 37 1C.
In situ zymography SW620 cells (2 Â 10 4 cell /35-mm glass-base dish (Iwaki, Chiba, Japan)) were infected with adenovirus at MOI of 600. Sixteen hours after infection, the cells were treated with freshly neutralized Cellmatrix type I collagen (Nitta Gelatin, Osaka, Japan) and FITC-labeled DQ type I collagen (Molecular Probes, Eugene, OR, USA) as described previously (Kondo et al., 2007) . After additional 48-h incubation, FITC signals, representing cleaved DQ type I collagen, were recorded using the confocal laser microscope (Olympus, Tokyo, Japan).
Treatment with inhibitors SW620 cells (1 Â 10 5 ) plated onto regular or type I collagencoated six-well plates (Iwaki) on the previous day were exposed to an inhibitor for 48 h. PP2, LY294002, PD98059, GF109203X and Toxin B were purchased from Calbiochem (Rockville, ML, USA).
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